PURPOSE: Trajectory models have been shown to (1) identify groups of patients with similar patterns of medication filling behavior and (2) summarize the trajectory, the average adherence in each group over time. However, the association between adherence trajectories and clinical outcomes remains unclear. This study investigated the association between 12-month statin trajectories and subsequent cardiovascular events. METHODS: We identified patients with insurance coverage from a large national insurer who initiated a statin during January 1, 2007 to December 31, 2010. We assessed medication adherence during the 360 days following initiation and grouped patients based on the proportion of days covered (PDC) and trajectory models. We then measured cardiovascular events during the year after adherence assessment. Cox proportional hazards models were used to evaluate the association between adherence measures and cardiovascular outcomes; strength of association was quantified by the hazard ratio, the increase in model C-statistic, and the net reclassification index (NRI). RESULTS: Among 519 842 statin initiators, 8777 (1.7%) had a cardiovascular event during follow-up. More consistent medication use was associated with a lower likelihood of clinical events, whether adherence was measured through trajectory groups or PDC. When evaluating the prediction of future cardiovascular events by including a measure of adherence in the model, the best model reclassification was observed when adherence was measured using three or four trajectory groups (NRI = 0.189; 95% confidence interval: [0.171, 0.210]). CONCLUSIONS: Statin adherence trajectory predicted future cardiovascular events better than measures categorizing PDC. Thus, adherence trajectories may be useful for targeting adherence interventions.
PURPOSE: Trajectory models have been shown to (1) identify groups of patients with similar patterns of medication filling behavior and (2) summarize the trajectory, the average adherence in each group over time. However, the association between adherence trajectories and clinical outcomes remains unclear. This study investigated the association between 12-month statin trajectories and subsequent cardiovascular events. METHODS: We identified patients with insurance coverage from a large national insurer who initiated a statin during January 1, 2007 to December 31, 2010. We assessed medication adherence during the 360 days following initiation and grouped patients based on the proportion of days covered (PDC) and trajectory models. We then measured cardiovascular events during the year after adherence assessment. Cox proportional hazards models were used to evaluate the association between adherence measures and cardiovascular outcomes; strength of association was quantified by the hazard ratio, the increase in model C-statistic, and the net reclassification index (NRI). RESULTS: Among 519 842 statin initiators, 8777 (1.7%) had a cardiovascular event during follow-up. More consistent medication use was associated with a lower likelihood of clinical events, whether adherence was measured through trajectory groups or PDC. When evaluating the prediction of future cardiovascular events by including a measure of adherence in the model, the best model reclassification was observed when adherence was measured using three or four trajectory groups (NRI = 0.189; 95% confidence interval: [0.171, 0.210]). CONCLUSIONS: Statin adherence trajectory predicted future cardiovascular events better than measures categorizing PDC. Thus, adherence trajectories may be useful for targeting adherence interventions.
Authors: Jennifer L Hargrove; Virginia Pate; Carri H Casteel; Yvonne M Golightly; Laura R Loehr; Stephen W Marshall; Til Stürmer Journal: Am J Hypertens Date: 2017-10-01 Impact factor: 2.689
Authors: Wei-Hsuan Lo-Ciganic; Julie M Donohue; Bobby L Jones; Subashan Perera; Joshua M Thorpe; Carolyn T Thorpe; Zachary A Marcum; Walid F Gellad Journal: J Gen Intern Med Date: 2016-05-26 Impact factor: 5.128
Authors: Aisha Vadhariya; Marc L Fleming; Michael L Johnson; E James Essien; Omar Serna; Tara Esse; Jeannie Choi; Susan H Boklage; Susan M Abughosh Journal: Am Health Drug Benefits Date: 2019 Jun-Jul
Authors: Chelsea E Hawley; Julie C Lauffenburger; Julie M Paik; Deborah J Wexler; Seoyoung C Kim; Elisabetta Patorno Journal: Diabetes Care Date: 2022-03-01 Impact factor: 19.112
Authors: Chandrasekar Gopalakrishnan; Rishi J Desai; Jessica M Franklin; Yinzhu Jin; Joyce Lii; Daniel H Solomon; Jeffrey N Katz; Yvonne C Lee; Patricia D Franklin; Seoyoung C Kim Journal: Arthritis Care Res (Hoboken) Date: 2022-04-22 Impact factor: 5.178
Authors: Enrica Menditto; Caitriona Cahir; Sara Malo; Isabel Aguilar-Palacio; Marta Almada; Elisio Costa; Anna Giardini; María Gil Peinado; Mireia Massot Mesquida; Sara Mucherino; Valentina Orlando; Carlos Luis Parra-Calderón; Enrique Pepiol Salom; Przemyslaw Kardas; Bernard Vrijens Journal: Int J Environ Res Public Health Date: 2021-05-03 Impact factor: 3.390